FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386845675> ?p ?o ?g. }

• W4386845675 abstract "Paracetamol is one of the most widely used drug in the world for the management of pain or fever, in particular among older people aged 60 years or older.1, 2 In France, the consumption of the drug is currently the highest in Europe, with an increase of 53% from 2006 to 2015.3 As paracetamol was considered safe at therapeutic doses, it has been recommended as a first-line drug in pain management guidelines, especially for aged and frail patients.4 However, the pharmacokinetic of paracetamol may be influenced by physiological and pathological changes in older patients, especially those who are underweight or frail.2 Studies have reported a reduction of paracetamol clearance with aging and frailty, resulting in an increase of paracetamol serum levels.5, 6 Moreover, liver damage caused by paracetamol at high dose can occur particularly into older patients who are malnourished or weigh <50 kg.7 One explanation is the increase of the toxic metabolite of paracetamol, N-acetyl-p-benzoquinone-imine, by glutathione depletion.8 In addition, the impact of multimorbidity and polypharmacy prevalent in older people on the pharmacokinetics of paracetamol remains to be investigated.9 Studies supported the evidence of a clinically significant interaction between warfarin and paracetamol, requiring close monitoring taking the drugs in combination.10, 11 Some epidemiological studies also suggested that chronic paracetamol use might be associated with renal or cardiovascular disease, gastrointestinal disorders, and asthma, but these findings were inconclusive and had no proven relevance to acute episodic use.12, 13 However, it remains the analgesic of choice in the older patient and the appropriateness of its continuation should be regularly reassessed including pain evaluation. Notwithstanding the concern regarding potentially excessive dosing in frail and low-body-weight older people in hospital, there are few published data on the subject outlining the prescribing and monitoring practices of paracetamol in these people. Therefore, the aim of this study was to describe in real practice the paracetamol use in elderly hospitalized patients. A retrospective observational study of patients hospitalized into a French geriatric public hospital for oral paracetamol prescriptions was performed between January 2021 and December 2021. Ethical approval from the Ethic Committee of the Paul Doumer Hospital was waived before the start of data collection, as the study was exclusively observational. Inclusion criteria comprised participants aged over 70 years and who were admitted to hospital for more than 7 days in the acute geriatric unit (AGU), care and rehabilitation unit (CRU), and long-term care unit (LTCU). Exclusion criteria comprised patients who had received paracetamol-containing combination analgesics and drugs interacting severely or moderately based on the Micromedex database (isoniazid, imatinib, warfarin, phenytoin, acenocoumarol, zidovudine, carbamazepine, and ethanol). The paracetamol combination with analgesic has been excluded from our therapeutic arsenal because of the higher potential for drug overdose. So, we decide arbitrary to exclude this combination. Subjects were identified through a retrospective review of our electronic prescribing and medical records of all patients with oral paracetamol prescription. The physician assigned to analyze and collect medical information extracted data from subjects who are eligible for inclusion. Fully independent of the study, he selected 30 patients for this study. The data gathered information regarding the patient demographics, biochemical measurements, paracetamol administration, related drugs, and the duration of the patients’ stay. In addition, the paracetamol dose received each day, the duration of paracetamol prescription for regular administration or when needed, the cumulative dose, and the reassessment of prescription were also recorded from electronic records. Physicians collected data. Paracetamol dosing was compared with consensus guidelines that recommended a maximum safe dose <4 g/24 h with a dosage adjustment in the context of comorbidities and co-prescription of anticoagulants in patients over 65–70 years of age.14, 15 Moreover, some guidelines included warning that some patients may be at the risk of experience toxicity with a body-weight under 50 kg and suggested a dose reduction when paracetamol is used regularly in these patients.4, 15, 16 Data were provided and analyzed using Microsoft Excel for mean, SD, and extrema. The demographic and chemical characteristics of participants are summarized in Table 1. The age ranged from 71 to 97 years of age, with an average of 87.3 (SD ± 6.5). The average length of stay was 60 days (SD ± 73) with range from 7 to 305 days. No participant had an alcoholism addiction or hepatic failure (Table 1). The modification of diet in renal disease was classified to Stage 3 to 5 in 13 patients, equivalent to a moderate decrease to renal failure (Table 1). From the 30 patients, all patients are regarded as frail, including four with a weight of <50 kg. For most patients, the inpatient paracetamol order was for when needed (n = 23, 74%) (Table 2). The paracetamol order was not reported in 19% of patients. All patients received a theoretical paracetamol dose under 4 g per day as recommended in consensus guidelines (Table 2). The duration of prescription differed depending in the clinical unit (Table 2). In AGU and CRU, the mean of prescription days was fairly short with 8 (±4, range 1–14) days and 44 (±28, range 9–90) days, respectively. As opposed, in LTCU where the average of length of stay is extensive, the mean of prescription days was high with 824 (±687, range 24–1996) days. The mean daily dose was under 60 mg/kg but with a wide range of 30.7–85.7 mg/kg (Table 2). The patients weighed <50 kg received a paracetamol dose higher than recommended in consensus guidelines (mean daily dose 74.2 ± 8.5 mg/kg, range 62–85.7). The theoretical cumulative paracetamol dosing for patients admitted in AGU, CRU, and LRCU was estimated to 24 ± 12, 125 ± 85, and 2472 ± 2061 g, respectively. However, the cumulative paracetamol dosing actually received was 9 ± 11 (0–42) for AGU, 31 ± 37 (2–146) for CRU, and 614 ± 556 (22–1536) for LCRU (Table 2). This variation could be explained by the paracetamol order in “when needed” and the respect of paracetamol administration by nurses correlated with the pain assessment. In eight patients, the paracetamol prescription was initiated, despite no pain being recorded in the evaluation of the pain (Table 2). The management of pain in the older population varies from that of younger people. Indeed, the clinical expressions of pain are often complex and multifactorial in the elderly population. In addition, older people may underreport pain particularly for patients with cognitive disorders. Although changes with normal aging can affect disposition, metabolism, and responses to analgesic medications.14 As paracetamol is not associated with significant adverse effects than traditional nonsteroidal anti-inflammatory drugs, paracetamol is recommended as first-line therapy for the management of pain in older adults. Likewise, some studies reported paracetamol regimens in older adults that involved administrations >3 or 4 g/d.2, 17, 18 In a French study, 50% of patients aged >75 years with risk factor for toxicity (low body weight or malnutrition) had their paracetamol dose not reduced.17 In a recent Swiss study, the maximal daily dose of 60 mg/kg was exceeded in 30.1% of patients weighing <50 kg, as well as in 42.3% of patients weighing <60 kg.18 In our hospital, paracetamol was the first drug taken in units. The paracetamol order was mainly in “when needed” without time prescription restriction in LTCU. However, the paracetamol dosing was systematically 1 g × 3 per day regardless of the patient's weight or frailty. In 19% of patients, the paracetamol dose was higher (range 62–85.7 mg/kg/d) than recommended by consensus guidelines, in particular for patients in AGU. Therefore, admission in different ward unit might affect the management of paracetamol. This situation may indicate insufficient clinician awareness of guidelines for paracetamol use in the frail and underweight older population. Nevertheless, the reasons why paracetamol doses were not adjusted particularly to low-weight or frailty older population were not investigated. One contributing factor could be the absence of local guidelines for the paracetamol prescription in the elderly. Another explanation may be the lack of decision support for paracetamol dosing integrated into the electronic medication system. The implementation of an electronic tool with alerts for excessive paracetamol in a Swiss hospital reported >70% of excessive dosing and permitted pharmaceutical interventions.18 At the study hospital, it has been proposed setting up a protocol for prescribing paracetamol at 1 g three times a day for the oral route and 15 mg/kg/d for the intravenous route. Moreover, support on the correlation between pain assessment performed by nurses and paracetamol use was provided to ensure proper administration of the drug. For the low-weight and frailty patients, pharmacists proposed by electronic prescribing system to adapt the paracetamol dosing to maximum 50 mg/kg/d. Patients were prescribed paracetamol doses that were rarely adapted to the weight or frailty of older population, and for a prolonged period into LTCU. The use of an automatic electronic alert system for paracetamol prescriptions and cumulative daily dose may reduce the risk of overdose. Frederic Baud: Conceptualization; data curation; formal analysis; funding acquisition; methodology; resources; supervision. Nadia Ladjouzi: Validation; visualization. Jihène Ben Hassen: Validation. Nesrine El Omeiri: Validation. Hendriniainia Raveloson: Validation. Lucile Brondin: Visualization. Camille Ben Rahal: Visualization. Cid Ould Ouali: Validation; visualization. Georges Zouloumis: Validation; visualization. Joël Schlatter: Conceptualization; data curation; formal analysis; funding acquisition; methodology; validation; writing—original draft. All authors have read and approved the final version of the manuscript. Corresponding author had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. No applicable. The authors declare no conflict of interest. The requirement for informed consent was waived by the Ethic Committee of the Paul Doumer Hospital because of the retrospective nature of the study. The lead author Joël Schlatter affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. All relevant data have been presented in the manuscript and further inquiry can be directed to the corresponding author." @default.
• W4386845675 created "2023-09-20" @default.
• W4386845675 creator A5000643669 @default.
• W4386845675 creator A5011839065 @default.
• W4386845675 creator A5015979635 @default.
• W4386845675 creator A5021744927 @default.
• W4386845675 creator A5056101863 @default.
• W4386845675 creator A5063745601 @default.
• W4386845675 creator A5088413919 @default.
• W4386845675 creator A5092898871 @default.
• W4386845675 creator A5092898872 @default.
• W4386845675 creator A5092898873 @default.
• W4386845675 date "2023-09-01" @default.
• W4386845675 modified "2023-10-18" @default.
• W4386845675 title "Paracetamol prescriptions in older people hospitalized in a French geriatric hospital" @default.
• W4386845675 cites W1494229485 @default.
• W4386845675 cites W1987367293 @default.
• W4386845675 cites W1991300596 @default.
• W4386845675 cites W2070782396 @default.
• W4386845675 cites W2097972249 @default.
• W4386845675 cites W2108368037 @default.
• W4386845675 cites W2146441593 @default.
• W4386845675 cites W2380527587 @default.
• W4386845675 cites W2766496200 @default.
• W4386845675 cites W2791970879 @default.
• W4386845675 cites W2806798661 @default.
• W4386845675 cites W2809419493 @default.
• W4386845675 cites W2940285062 @default.
• W4386845675 cites W3097862772 @default.
• W4386845675 cites W3188836359 @default.
• W4386845675 cites W4200435970 @default.
• W4386845675 cites W4229458520 @default.
• W4386845675 cites W4235018718 @default.
• W4386845675 doi "https://doi.org/10.1002/hsr2.1565" @default.
• W4386845675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37732103" @default.
• W4386845675 hasPublicationYear "2023" @default.
• W4386845675 type Work @default.
• W4386845675 citedByCount "0" @default.
• W4386845675 crossrefType "journal-article" @default.
• W4386845675 hasAuthorship W4386845675A5000643669 @default.
• W4386845675 hasAuthorship W4386845675A5011839065 @default.
• W4386845675 hasAuthorship W4386845675A5015979635 @default.
• W4386845675 hasAuthorship W4386845675A5021744927 @default.
• W4386845675 hasAuthorship W4386845675A5056101863 @default.
• W4386845675 hasAuthorship W4386845675A5063745601 @default.
• W4386845675 hasAuthorship W4386845675A5088413919 @default.
• W4386845675 hasAuthorship W4386845675A5092898871 @default.
• W4386845675 hasAuthorship W4386845675A5092898872 @default.
• W4386845675 hasAuthorship W4386845675A5092898873 @default.
• W4386845675 hasBestOaLocation W43868456751 @default.
• W4386845675 hasConcept C159110408 @default.
• W4386845675 hasConcept C177713679 @default.
• W4386845675 hasConcept C194828623 @default.
• W4386845675 hasConcept C2426938 @default.
• W4386845675 hasConcept C3019887659 @default.
• W4386845675 hasConcept C36434225 @default.
• W4386845675 hasConcept C545542383 @default.
• W4386845675 hasConcept C71924100 @default.
• W4386845675 hasConcept C74909509 @default.
• W4386845675 hasConceptScore W4386845675C159110408 @default.
• W4386845675 hasConceptScore W4386845675C177713679 @default.
• W4386845675 hasConceptScore W4386845675C194828623 @default.
• W4386845675 hasConceptScore W4386845675C2426938 @default.
• W4386845675 hasConceptScore W4386845675C3019887659 @default.
• W4386845675 hasConceptScore W4386845675C36434225 @default.
• W4386845675 hasConceptScore W4386845675C545542383 @default.
• W4386845675 hasConceptScore W4386845675C71924100 @default.
• W4386845675 hasConceptScore W4386845675C74909509 @default.
• W4386845675 hasIssue "9" @default.
• W4386845675 hasLocation W43868456751 @default.
• W4386845675 hasLocation W43868456752 @default.
• W4386845675 hasOpenAccess W4386845675 @default.
• W4386845675 hasPrimaryLocation W43868456751 @default.
• W4386845675 hasRelatedWork W1972039098 @default.
• W4386845675 hasRelatedWork W2285874551 @default.
• W4386845675 hasRelatedWork W2408321816 @default.
• W4386845675 hasRelatedWork W3089436011 @default.
• W4386845675 hasRelatedWork W3185687918 @default.
• W4386845675 hasRelatedWork W3210863890 @default.
• W4386845675 hasRelatedWork W4210358854 @default.
• W4386845675 hasRelatedWork W4232842025 @default.
• W4386845675 hasRelatedWork W4288047948 @default.
• W4386845675 hasRelatedWork W4362713464 @default.
• W4386845675 hasVolume "6" @default.
• W4386845675 isParatext "false" @default.
• W4386845675 isRetracted "false" @default.
• W4386845675 workType "article" @default.